Urolithin A and EGCG Combo Rescues Mitochondria in Alzheimer's Tau Model

Mitochondrial dysfunction is increasingly recognized as a central driver of Alzheimer's disease pathology, not merely a downstream consequence. When the protein Tau becomes abnormally phosphorylated, it disrupts mitochondrial structure and function, contributing to neuronal death and cognitive decline. Finding ways to restore mitochondrial health in this context could open new therapeutic avenues.

This study from Texas Tech University used immortalized mouse hippocampal HT22 neurons engineered to express mutant Tau (mTau-HT22) as a tauopathy cell model. Researchers treated these cells with four known mitophagy enhancers — urolithin A, actinonin, tomatidine, and nicotinamide riboside — then measured gene expression, protein levels, cell viability, mitochondrial respiration, and mitochondrial morphology via electron microscopy.

Untr eated mTau-HT22 cells displayed a striking pattern of mitochondrial damage: excess fission (fragmentation), reduced fusion, suppressed biogenesis, impaired mitophagy, downregulated synaptic markers, and diminished oxygen consumption. All four mitophagy-enhancing compounds reversed these deficits to varying degrees, restoring marker expression and functional metrics. Urolithin A — a natural compound derived from gut metabolism of pomegranate and berry polyphenols — consistently showed the strongest individual effects across measured outcomes.

A particularly notable finding was the synergistic benefit of combining urolithin A with EGCG (epigallocatechin gallate, a green tea catechin). This combination improved mitochondrial respiratory function beyond what either compound achieved alone, suggesting complementary mechanisms of action worth exploring further.

While promising, the study is limited to a single cell-line model, and translation to human disease requires animal and eventually clinical validation. Nevertheless, the results position mitophagy enhancement — especially via urolithin A, alone or combined with EGCG — as a compelling, accessible target for Alzheimer's therapeutic development.